Fig. 3From: Longitudinal NGAL and cystatin C plasma profiles present a high level of heterogeneity in a mixed ICU populationMaximum plasma NGAL and CysC during 7-day ICU admission. (a) AKI vs. non-AKI. (b) AKI vs. non-AKI based on APACHE IV score upon admission. (c) AKI only patients meeting Major Adverse Kidney Event (MAKE) outcomes. MAKE outcomes defined as AKI at ICU discharge, renal replacement therapy requirement during ICU admission or death during ICU admissionBack to article page